New molecule interferes with heat shock protein activities

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 11
Volume 18
Issue 11

Researchers had identified a small molecule that inhibits the heat shock protein HSP70. They also demonstrated in their animal experiment that the HSP inhibitor could stop tumor formation and significantly extend survival.

Researchers had identified a small molecule that inhibits the heat shock protein HSP70. They also demonstrated in their animal experiment that the HSP inhibitor could stop tumor formation and significantly extend survival.

The Philadelphia-based group showed that the inhibitor, called PES, interacted with HSP70 by blocking its stress-relieving functions. It also induces HSP70-dependent cell death by disrupting the cell’s ability to remove damaged components (Mol Cell 9:15-27, 2009).

The research was conducted by Donna George, PhD, associate professor of genetics, and Julie Leu, PhD, assistant professor of genetics, both at the University of Pennsylvania School of Medicine, in collaboration with the lab of Maureen Murphy, PhD, at Fox Chase Cancer Center.

PES seems to be specifically targeting HSP70, according to Dr. George. While studies in humans are still needed, “the exciting part is that this is a pathway and a protein target that clearly is important for cancer cells,” she said.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content